Led · Seed · Jul 2026

Accipiter Biosciences applies artificial-intelligence tools developed at the University of Washington’s Institute for Protein Design to engineer proteins capable of binding multiple cellular targets simultaneously. The company runs both partnered programs (including collaborations and license agreements with Pfizer and Kite Pharma) and internal drug-development programs, with a current focus on immunology-related conditions alongside a lead oncology program. Its Pfizer agreement included an upfront payment and the potential to earn over $330 million in milestones and royalties, and the Kite/Gilead collaboration is similarly structured. Accipiter launched in March 2023 and has grown its team to 22 employees, planning to expand to about 30 within the next six to twelve months. With the recent $10.5 million seed top-up (bringing total raised to about $23.2 million), the company intends to accelerate advancement of three to four programs into clinical trials versus its original plan of one or two.

Participated · Series B · Nov 2025

Beacon Biosignals develops FDA-cleared wearable EEG technology combined with advanced AI to capture and analyze real-world neural data. Its platform provides clinicians and biopharma partners with objective measures of brain function intended to accelerate research, improve diagnostics and guide new treatments across neurology, psychiatry and sleep medicine. The company is led by CEO Jacob Donoghue and is based in Boston, MA. Beacon reported cumulative funding of over $132M following the Series B extension. The company plans to use the new proceeds to further scale at-home EEG deployments and expand its analytics capabilities to support diagnostics, clinical trials and precision medicine.

Participated · Equity · Jun 2024

LOGZGROUP runs a network of IT-specialized employment-transition schools and an employer-facing "disability employment cloud" that together aim to place people with disabilities into IT roles. The company emphasizes IT curricula (programming, web design) and reports that about 41% of graduates secure IT jobs with a workplace retention rate of 94%. Its schools operate across 40 locations nationwide and the business has grown to an industry top-five position. LOGZGROUP’s stated mission is to "remove the line of disability," and it plans to invest in hiring, technology, and organizational development to scale operations. The company recently completed a capital raise (described below) and says the funds will be used to accelerate recruitment, technical capability, and organizational strength to expand placements and support employers’ disability-hiring needs. Headquarters are in Minato-ku, Tokyo.

Led · Equity · Jun 2024

Ascentage Pharma (亚盛医药) is a pharmaceutical company. On June 20, 2024 the company completed an equity investment transaction with Takeda Pharmaceutical. The transaction funds have been received and the deal was formally closed. Under the agreement Ascentage allotted 24,307,322 subscription shares to Takeda at HKD24.09850 per share (approximately USD3.08549 per share). The investment amount reported in the article is USD75 million. The article does not provide operating metrics, past rounds, or specific use of proceeds. Ascentage Pharma is a global clinical-stage biopharmaceutical company focused on designing small-molecule therapies that inhibit protein-protein interactions to restore apoptosis. Its pipeline comprises seven clinical candidates, including APG-1252, a highly potent Bcl-2/Bcl-xL inhibitor, plus programs aimed at IAP and MDM2-p53 pathways and next-generation tyrosine kinase inhibitors. The company’s technology is based on work from the University of Michigan and it is led by Dr. Dajun Yang, Chairman and CEO. Ascentage completed an approximately $150M Series C that brought total funding to around $240M. The company intends to use the proceeds to support its broad apoptosis-targeted pipeline and to build out R&D centers and manufacturing facilities. Ascentage positions itself as a globally-focused developer advancing multiple clinical-stage candidates for cancer and other diseases. Ascentage Pharma discovers and develops small-molecule targeted therapeutics for cancers, hepatitis B and age-related diseases using proprietary protein–protein interaction drug discovery technologies. The company holds over 80 international patents and currently has six small-molecule drugs in Phase I–II trials in the US, Australia and China, with additional programs in preclinical stages. Its R&D pipeline includes inhibitors of IAP, Bcl-2/Bcl-xL and MDM2–p53, second- and third-generation kinase inhibitors to overcome mutant resistance, and inhibitors of epigenetics. On December 22, 2016 Ascentage obtained FDA IND approval for APG-1252, a novel Bcl-2/Bcl-xL inhibitor. The company intends to use new capital to further accelerate its pipeline of apoptosis-targeted small molecules. Ascentage is led by co-founder, chairman and CEO Dajun Yang, MD, Ph.D. Ascentage Pharma focuses on discovery and development of targeted small-molecule cancer therapies, with programs spanning preclinical to mid-stage clinical trials. Its pipeline includes a pan Bcl-2 inhibitor in Phase II trials in China and the US and a small-molecule IAP antagonist in Phase I trials in China and Australia. The company has one drug submitted for IND approval, two additional drugs slated for IND filing in 2015, and several preclinical discovery programs targeting key oncogenic drivers. Ascentage has raised financing to support clinical development, CMC upgrades and manufacturing expansion. The company previously received a US$3M strategic investment from 3SBio to advance its programs and infrastructure. Operations are oriented toward advancing multiple candidate drugs through IND and clinical milestones.

Participated · Equity · Jul 2023

Crescendo Biologics is a clinical-stage immuno-oncology company based in Cambridge, UK, that develops Humabody® VH-based multi‑functional therapeutics. Its lead proprietary programme, CB307, is a half-life extended CD137 x PSMA bispecific designed to activate tumour-specific T cells within the tumour microenvironment while avoiding systemic toxicity. The company uses a patented transgenic mouse platform to generate fully human VH domain building blocks (Humabody VH) that can be configured for novel pharmacology and improved biodistribution. CB307 is in an adaptive Phase 1b clinical trial with a monotherapy expansion cohort underway in PSMA+ metastatic castration-resistant prostate cancer and a planned pembrolizumab combination expansion cohort expected to start in Q3 2023. Beyond CB307, Crescendo has global discovery and development collaborations with Takeda and BioNTech and an exclusive worldwide licensing agreement with Zai Lab for ZL-1102, which is expected to enter global Phase 2 for psoriasis. The company recently secured additional financing to enable acceleration of its clinical programme. Crescendo Biologics develops potent, multi-functional Humabody® therapeutics for oncology, with a particular focus on novel targeted T‑cell engagers. Its lead programme, CB307, is designed to stimulate local activation of tumour-specific T‑cells and the company plans to advance CB307 into the clinic. The newly raised funds will also be used to expand Crescendo’s internal pipeline of Humabody-based products and pursue strategic partnerships. Crescendo has a collaboration with Takeda Pharma worth up to $790 million. The company is headquartered in Cambridge, England. The $70 million Series B will fund clinical entry and further platform development. Crescendo Biologics is a Cambridge, UK–based company focused on the discovery and development of human VH antibody fragment therapeutics. The company leverages its VH platform to develop topical biologics for psoriasis and multivalent products for oncology indications. Led by CEO Mike Romanos, Crescendo aims to advance multiple in-house development programmes. The firm raised additional capital in a Series A financing to support those programmes. The Series A was completed with a final close that increased the round size. No operating metrics were disclosed in the article. Crescendo Biologics is a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics. Led by CEO Mike Romanos, the company uses a VH fragment discovery platform to advance in-house development programmes in inflammation and oncology. It is establishing an internal pipeline that includes a topical biologic for psoriasis and multivalent products for oncology indications. In December 2013 Crescendo raised £17.5m ($28m) in a Series A financing to support these efforts. The company intends to use the funds to advance its inflammation and oncology programmes to the clinic. In conjunction with the funding, Rob Woodman of Imperial Innovations joined Crescendo’s board. Crescendo Biologics is a Cambridge, UK–based developer of antibody fragment technologies and a transgenic mouse platform. The platform is designed to rapidly generate high‑affinity human heavy chain antibodies that readily yield VH fragments with no requirement for humanisation. The company aims to apply this technology to create next‑generation targeted biological therapeutics based on fragment antibodies. It has appointed Dr Mike Romanos as CSO; he has extensive experience in biopharmaceutical R&D. Crescendo raised £4.5m in a seed funding round led by Sofinnova Partners, with Aitua, Avlar BioVentures and the Rainbow Seed Fund participating. The proceeds will be used to advance development of the platforms and to initiate the development of proprietary therapeutics.